{"id":132167,"date":"2026-07-20T14:59:11","date_gmt":"2026-07-20T14:59:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/132167\/"},"modified":"2026-07-20T14:59:11","modified_gmt":"2026-07-20T14:59:11","slug":"citi-lifts-novo-nordisk-target-on-strong-glp-1-pill-launch","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/132167\/","title":{"rendered":"Citi lifts Novo Nordisk target on strong GLP-1 pill launch"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/0A93BED704B6B648A6F37EA4A73FAD60D8F5C3100436AFCCDDC32BADF6C98F63\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fproactive_us_504%2Fd9abb7d044ffe9e44082cbd379fd0a96\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Citi lifts Novo Nordisk target on strong GLP-1 pill launch\" height=\"540\" width=\"960\" class=\"yf-lglytj loader\"\/><\/a> Citi lifts Novo Nordisk target on strong GLP-1 pill launch Proactive uses images sourced from Shutterstock           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Citi has raised its price target on <a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:Novo%20Nordisk%20(NYSE%3ANVO);elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novo Nordisk (NYSE:NVO)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">Novo Nordisk (NYSE:NVO)<\/a> to DKK330 ahead of second-quarter results on 5 August, citing the strength of the Danish drugmaker&#8217;s Wegovy pill launch.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The broker lifted its 2026 sales and operating income estimates by 4% to 5%, and its earnings per share forecasts for 2027 to 2030 by around 7%, on currency movements and stronger second-quarter Wegovy trends.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The new target is based on 16 times 2027 earnings, up from 15 times, reflecting better Wegovy growth.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">For the second quarter, Citi forecasts adjusted operating income of DKK27.2 billion, down 9% at constant currencies, on sales of DKK72.7 billion, down 1%, both excluding US 340B rebate effects.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The declines mainly reflect continued price pressure across both the obesity and diabetes franchises, partially offset by the oral Wegovy launch, forecast to contribute DKK4 billion, or $630 million.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The key question is whether, and by how much, Novo raises full-year guidance given strong prescription trends for both pill and injectable Wegovy through the launch of Eli Lilly&#8217;s rival Foundayo.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Citi sees an upgrade as expected and already priced in, and kept its neutral rating for that reason.  <\/p>\n","protected":false},"excerpt":{"rendered":"Citi lifts Novo Nordisk target on strong GLP-1 pill launch Proactive uses images sourced from Shutterstock Citi has&hellip;\n","protected":false},"author":2,"featured_media":132168,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1893,64221,272,7624],"class_list":["post-132167","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-citi","tag-income-estimates","tag-novo-nordisk","tag-target"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116952902529910370","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/132167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=132167"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/132167\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/132168"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=132167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=132167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=132167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}